Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

NCT05640726 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT05640726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05640726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
May 1, 2023
Completion date
May 1, 2026
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer